Lexicon Pharma (LXRX) Announces Sotagliflozin Phase 2 Met Primary Endpoint in T2D
Tweet Send to a Friend
Lexicon Pharmaceuticals, Inc. (NASdAQ: LXRX) announced that the Phase 2 dose-ranging, inTandem4 clinical trial of dual SGLT1 and SGLT2 inhibitor ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
